Diabetes news from FiercePharma
NewsNew drug-spending leader: Diabetes
New data on pharma sales details some big shifts in spending. Diabetes meds have displaced cholesterol drugs as the Read more...
Novartis restricts Zelnorm to emergencies
Goodbye cruel world. Novartis is pulling the irritable bowel med Zelnorm off the market almost completely, saying it will supply the drug only for emergency use. And even in emergencies, Zelnorm will Read more...
Caraco to withdraw misshaped metformin
A couple of weeks ago, the Los Angeles Times ran a big package about generic meds. Are they really as good as Read more...
Judge: FDA can't police drugs alone
As Eli Lilly went up to bat in the big Zyprexa trial in Alaska, Read more...
Supremes vote 4-4 in pre-emption suit
The Supreme Court came and saw and voted but left no clarity on pre-emption behind. Because Chief Justice John Roberts sat out the case, the vote ended in a 4-4 tie, automatically affirming the lower Read more...
SPOTLIGHT: Drug scandals cause second-guessing
Recent drug news--from Zyprexa's weight gain-and-diabetes problem to Avandia's heart attack warning to the recent hoopla over Vytorin--have some people asking whether drug therapy is all it's Read more...
SPOTLIGHT: Sciele readies six meds for market
Sciele Pharma expects to launch six new products in 2008, executives announced, including a new formulation of its blood pressure drug Sular and two forms of the Prandin drug for Type II diabetes, Read more...
FDA unsure consumers can self-Mevacor
No crystal ball here: In reviewing Merck's application to convert Read more...
Lilly declares a truce in diabetes rep war
For a while there it looked like Eli Lilly and Novo Nordisk were competing to see who could deploy the biggest army of diabetes reps in the U.S. While most pharma companies were chopping sales Read more...
SPOTLIGHT: CV's Ranexa wins FDA review
CV Therapeutics is making progress in its pursuit of new indications for Ranexa, its angina drug for patients who haven't responded to other therapies. The agency agreed to consider its application Read more...
| Press ReleasesPRESS RELEASE: AtheroGenics Says Stops Highest Dose of Drug in Diabetes Trial AtheroGenics Says Stops Highest Dose of Drug in Diabetes Trial ATLANTA, GA -- Nov 9, 2007 -- AtheroGenics, today announced that after discussions with the U.S. Food and Drug Administration (FDA), Read more... PRESS RELEASE: Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes CARLSBAD, Calif., Oct. 18 -- Isis Pharmaceuticals, Inc. today announced that it has Read more... PRESS RELEASE: Eli Lilly and Company in $494 Million Deal for Diabetes Drug Eli Lilly and Company in $494 Million Deal for Diabetes Drug ROCKVILLE, Md., and INDIANAPOLIS, Oct. 18 -- Eli Lilly and Company and MacroGenics, Inc. today announced that the two companies have Read more... PRESS RELEASE: Exelixis Diabetic Nephropathy Drug Trial Fails Goal Exelixis Diabetic Nephropathy Drug Trial Fails Goal SOUTH SAN FRANCISCO, Calif., Oct. 16 -- Exelixis announced that a recently completed phase 2 trial of XL784 did not meet its primary endpoint of Read more... |
Get more Diabetes coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight